Source of Peptide synthesis

{{Infobox concept | name = Peptide synthesis | subtitle = Manufacture | image = spps-cycle.svg | caption = Coupling and deprotection repeated once per residue, from the C-terminus. | Direction = C-terminus to N-terminus | Dominant technique = [[Solid-phase peptide synthesis|Solid phase]], Fmoc chemistry | Alternative = Solution phase; recombinant expression }} {{hatnote|For the dominant technique in practice, see [[Solid-phase peptide synthesis]].}} '''Peptide synthesis''' is the chemical assembly of a peptide from protected amino acid building blocks. It proceeds from the C-terminus towards the N-terminus, in the opposite direction to biological translation, because that ordering avoids racemisation of the activated residue.{{r|merrifield1963}} Chemical synthesis is the only practical route for peptides containing non-proteinogenic residues, and almost every engineered therapeutic peptide contains at least one — the α-aminoisobutyric acid of [[Semaglutide|semaglutide]] and [[Tirzepatide|tirzepatide]] cannot be introduced by a ribosome.{{r|behrendt2016}} Three approaches exist: [[Solid-phase peptide synthesis|solid-phase synthesis]], in which the growing chain is anchored to an insoluble support; [[Liquid-phase peptide synthesis|solution-phase synthesis]], in which it is not; and hybrid approaches in which fragments made on solid phase are joined in solution. Solid phase dominates for research quantities and for most therapeutic peptides.{{r|behrendt2016}} == The elementary cycle == Each residue is added by a two-step cycle. The N-terminal protecting group of the growing chain is removed, then the next amino acid — protected at its own N-terminus and on any reactive side chain — is activated and coupled.{{r|merrifield1963}} Protecting groups are what make selectivity possible. The temporary N-terminal group is removed once per cycle; side-chain groups are orthogonal to it and survive until final cleavage. The choice of scheme — Fmoc with acid-labile side chains, or Boc with more forcing conditions — defines the whole chemistry that follows. See [[Fmoc chemistry]]. Coupling is driven by an activating reagent that converts the carboxyl group into a reactive species. Reagent choice affects both speed and the degree of racemisation at the activated centre, and is one of the main levers in optimising a difficult sequence. See [[Peptide coupling reagent]].{{r|behrendt2016}} == Why yield falls with length == Because a peptide of ''n'' residues requires ''n'' couplings, overall yield is the product of the individual coupling yields. At 99% per coupling a 30-residue peptide is obtained in about 74% yield; at 98% it is about 55%; at 95% it is about 21%.{{r|behrendt2016}} The material lost is not simply absent — it is present as truncated and deletion sequences, which remain attached to the support and are cleaved along with the target. These are the impurities that dominate a [[Crude peptide|crude]] peptide and that a purity method must resolve. Difficult sequences make the arithmetic worse. Aggregation of the growing chain on the support hides the reactive terminus and depresses coupling yields locally, which is why particular regions of a sequence rather than the whole are usually responsible for a poor crude. See [[Solid-phase peptide synthesis]].{{r|merrifield1963}} == Downstream of the chain == Cleavage from the support releases the peptide and, in Fmoc chemistry, removes the side-chain protecting groups simultaneously in a single strongly acidic treatment. Scavengers are included to trap the reactive cations released, which would otherwise alkylate sensitive residues. See [[Resin cleavage]].{{r|behrendt2016}} The resulting crude is precipitated, then purified by [[Preparative HPLC purification|preparative chromatography]] and isolated by [[Lyophilisation|lyophilisation]]. Because the mobile phase is acidified with trifluoroacetic acid, the isolated solid is a [[Trifluoroacetate counterion|trifluoroacetate salt]] unless exchanged.{{r|usp1503}} Every stage leaves a signature that analysis can find: deletion sequences from coupling, oxidised and alkylated residues from cleavage, residual solvent from purification, counterion from the mobile phase. This is why a peptide impurity profile is informative about how a material was made, and why an itemised related-substances table is worth more than an aggregate figure.{{r|usp1503}} In regulated manufacture the same reasoning appears as the requirement to control process-related impurities at their source.{{r|ich_q7}} == References == {{reflist}} <ref name="merrifield1963">Merrifield RB. "Solid phase peptide synthesis. I. The synthesis of a tetrapeptide." ''Journal of the American Chemical Society'' 85(14):2149–2154 (1963). DOI:10.1021/ja00897a025.</ref> <ref name="behrendt2016">Behrendt R, White P, Offer J. "Advances in Fmoc solid-phase peptide synthesis." ''Journal of Peptide Science'' 22(1):4–27 (2016). DOI:10.1002/psc.2836. PMID 26785684.</ref> <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> <ref name="ich_q7">International Council for Harmonisation, ''Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients'' (2000).</ref> == See also == * [[Solid-phase peptide synthesis]] * [[Fmoc chemistry]] * [[Crude peptide]] * [[Preparative HPLC purification]] * [[Peptide coupling reagent]] * [[Resin cleavage]] {{DEFAULTSORT:Peptide synthesis}} [[Category:Peptide synthesis]] [[Category:Manufacturing and supply]] [[Category:Compounds and pharmacology]]